TB-500 Dosing Protocol: Injection, Pen Vial, Nasal Spray & Reconstitution (2026)

TB-500 Quick Start

TB-500 is a synthetic peptide based on the active region of Thymosin Beta-4 (Tβ4), a naturally occurring actin-binding protein. It is studied in cell-migration, soft-tissue, muscle, and wound-healing models, and is frequently paired with BPC-157 in tissue-repair research planning. It is on the WADA Prohibited List.

Quick reference Preclinical / early data

Class

Thymosin β-4 fragment

Formats

Vial · Pen vial · Nasal spray

Research focus

Cell migration, soft tissue

Schedule shape

Loading → maintenance

Vial size

10 mg

This guide is an educational research reference. It does not diagnose, treat, or prescribe, and is not medical advice. Consult a licensed clinician before considering any compound.

TB-500 Dosing Protocols

The injectable (subcutaneous), pen-vial and nasal-spray formats are documented as separate protocols. TB-500 is longer-acting than BPC-157, so research planning typically uses a twice-weekly loading phase followed by a weekly maintenance phase. Ranges are research-planning references, not personal dosing recommendations.

Injection — Subcutaneous

Reconstituted 10 mg vial, U-100 insulin syringe.

Phase	Per dose	Frequency
Loading	2–2.5 mg	2× weekly
Maintenance	2–2.5 mg	Weekly

10 mg + 2 mL BAC → 5 mg/mL · 2.5 mg = 0.5 mL = 50 units

Nasal Spray

Pre-mixed nasal spray, ready to use.

Phase	Per dose	# of sprays	Frequency
Loading	2.5 mg	13 sprays	2× weekly
Maintenance	2.5 mg	13 sprays	Weekly

Each 0.1 mL spray delivers 0.2 mg (200 mcg)

Pen Vial — Pre-Reconstituted 3 mL

Supplied already reconstituted to 3 mL — no mixing step. Doses are given in units, the scale a reusable pen dials in (300 units per vial). Pens step in whole or half units depending on the model — round any fractional figure to the nearest increment your device supports.

Phase	Per dose (units)	Delivers	Frequency
Loading	60–75 units	2–2.5 mg	2× weekly
Maintenance	60–75 units	2–2.5 mg	Weekly

10 mg in 3 mL → 33.3 mcg per unit · 300 units per pen · ~4 doses at 2.5 mg

Because TB-500 doses sit in the milligram range, one pen covers roughly four 2.5 mg doses — about two weeks of the loading phase. The lyophilized vial is the longer-running format for this compound.

TB-500 doses are in the milligram range, so the spray uses a concentrated 5 mL fill (0.2 mg/spray) and still requires multiple sprays per dose. The injection is the more compact route for this compound.

TB-500 Reconstitution Guide

TB-500 ships as a lyophilized powder. The BAC water volume sets the concentration and draw volume for the injectable vial. Nasal sprays and pen vials both ship ready to use — the pen at a fixed 3 mL fill, so no water is added to it at all.

Injection

BAC	Conc.	2.5 mg
2 mL	5 mg/mL	0.5 mL · 50 u
3 mL	3.33 mg/mL	0.75 mL · 75 u

Units are U-100 syringe units.

Pen Vial — 3 mL

Format	Conc.	2.5 mg
3 mL (as supplied)	3.33 mg/mL	0.75 mL · 75 u

Ships pre-reconstituted; no BAC water is added. 33.3 mcg per unit on a U-100 scale.

Reconstitution steps

Inspect the vial. Confirm label and intact powder.
Wipe the stoppers. Alcohol swab on both vials.
Draw BAC water. 2 mL into the injectable vial.
Inject down the wall. Release water slowly down the inside wall, not onto the powder.
Swirl, do not shake. Roll gently until clear.
Refrigerate. Store at 2–8 °C; do not freeze.

How to use the pen vial

Inspect the vial. Confirm the label and strength. The solution should be clear and colorless.
Never add water. A pen vial ships at its final 3 mL volume. Adding bacteriostatic water would dilute it and invalidate every unit figure on this page.
Load the vial into the pen. Unscrew the pen's cartridge holder, seat the vial, and screw the holder back on until firm.
Attach a fresh needle tip. Screw a new disposable pen needle onto the holder, then pull off the outer and inner caps. Use a new tip for every dose.
Prime the pen. Dial 2 units, hold the pen needle-up, tap the holder so any air rises to the top, and press the button until a drop appears at the tip. Repeat until it does.
Spin to the dose. Turn the dial to the unit figure from the table above. If you overshoot, spin back — never press the button to correct an overshoot.
Track what is left. At milligram-range doses one vial covers roughly four doses, so watch the remaining volume through the cartridge window and plan the cycle around it.
Inject and hold. Press the button all the way down, then keep the needle in place for about ten seconds before withdrawing so the full dose is delivered.
Remove and dispose of the needle. Unscrew the tip into a sharps container. Never store the pen with a needle attached — it lets solution leak out and air in.
Cap and refrigerate. Store the pen with the vial still seated at 2–8 °C. Do not freeze.

How to use the nasal spray

Prime first use. Pump 2–3 sprays into a tissue until a fine, even mist appears.
Position. Tilt the head slightly forward; insert the tip just inside one nostril, aimed slightly outward toward the ear — not at the septum.
Spray and breathe. Press once while breathing in gently; do not sniff hard, which sends the solution down the throat instead of onto the mucosa.
Alternate nostrils. For multi-spray doses, switch nostrils each spray to spread absorption and limit irritation.
Count per the protocol. Use the sprays-per-dose shown above; if a dose isn't a whole number, round up.
Between uses. Wipe the tip, recap, and refrigerate.

How TB-500 Works

TB-500 reproduces the actin-binding activity of Thymosin Beta-4. By regulating actin, a key cytoskeletal protein, it is reported in research to promote cell migration, support new blood-vessel formation (angiogenesis), and modulate inflammation — processes central to tissue repair. Its longer-acting profile, relative to BPC-157, is the basis for less frequent dosing.

Actin regulation

Binds G-actin and influences cytoskeletal dynamics underlying cell movement.

Cell migration

Reported to recruit repair cells into injured tissue.

Angiogenesis

Supports new blood-vessel formation in wound models.

Open question

Human efficacy and long-term safety are not established in controlled trials.

Who Should Avoid TB-500

Tested athletes

TB-500 / Tβ4 is on the WADA Prohibited List; use is an anti-doping rule violation.

Active or prior cancer

Pro-migratory, pro-angiogenic activity is a theoretical concern; discuss with a clinician.

Pregnancy & lactation

No human reproductive safety data.

Anyone seeking a treatment

TB-500 is a research compound, not a medical treatment.

TB-500 Side Effects & Safety

Injection-site reactions

Mild redness or lethargy after dosing are the most commonly reported short-term issues.

Theoretical proliferation risk

The same repair pathways could theoretically support unwanted cell growth; unresolved in humans.

Head-rush / fatigue

Transient effects are occasionally reported after larger doses.

Quality-control risk

Verify identity and purity against a Certificate of Analysis.

Timeline & What to Monitor

Timeframe	Commonly tracked	Notes
Week 1–2	Injection-site response, tolerability	Anti-doping violation applies immediately for tested athletes.
Week 2–4	Functional / range-of-motion self-report	Loading phase window in most planning.
Week 4–6+	Soft-tissue endpoints (animal models)	Transition to weekly maintenance; no human RCT covers this.

Research Evidence Context

Thymosin β-4 research

Tβ4 has been studied in wound, cardiac, and corneal repair models, underpinning TB-500 interest.

Preclinical TB-500

Animal data report cell-migration and recovery effects in soft-tissue injury.

Human data

Limited; no large RCT establishes efficacy for musculoskeletal repair.

Open question

Planning ranges are community-derived, not validated clinical doses.

Storage & Handling

State	Storage	Notes
Lyophilized (powder)	−20 °C long-term; fridge short-term	More stable than reconstituted solution.
Reconstituted (liquid)	2–8 °C	Use within ~3–4 weeks; do not freeze.
Appearance	Clear, colorless	Discard cloudy or particulate solutions.

Mistakes & Troubleshooting

Too many sprays feel impractical. The injection is the compact route for TB-500; the spray exists but needs multiple sprays per mg-range dose.
Wrong BAC volume. Recalculate concentration; injection assumes 2 mL, spray assumes 5 mL.
Missed dose. Resume the schedule; do not stack doses to compensate.
Left out overnight. Treat reconstituted solution as compromised and discard.

TB-500 vs BPC-157

Feature	TB-500	BPC-157
Class	Thymosin β-4 fragment	15-aa pentadecapeptide
Action	Actin / cell migration	Angiogenesis / VEGFR2
Dosing cadence	2× weekly → weekly	1–2× daily
Combined	Paired in the "Wolverine" approach — available pre-blended as BPC-157 / TB-500, or with GHK-Cu in GLOW.

Frequently Asked Questions

What is TB-500?

A synthetic peptide based on the active region of Thymosin Beta-4, studied for cell migration and soft-tissue repair. It is banned by WADA.

How is the injection dosed vs the nasal spray?

Separate protocols. Injection commonly references 2–2.5 mg, twice weekly loading then weekly. Because TB-500 doses are in the milligram range, the spray uses a concentrated 5 mL fill (0.2 mg/spray) and needs ~13 sprays to match 2.5 mg — the injection is the more compact route.

How is TB-500 reconstituted?

For injection, 10 mg in 2 mL BAC water gives 5 mg/mL, so 2.5 mg = 0.5 mL = 50 units. The spray ships pre-mixed and delivers 0.2 mg per spray.

How does TB-500 compare to BPC-157?

They act through different mechanisms (actin/migration vs angiogenesis) and are often paired. Both are available pre-blended as BPC-157 / TB-500, or with GHK-Cu added in GLOW.

What is the pen-vial format?

A 10 mg pen vial supplied already reconstituted to 3 mL, i.e. 300 units at 33.3 mcg per unit. A 2.5 mg reference dose is 75 units (0.75 mL), so one pen holds about four such doses.

Is this page medical advice?

No. It is an educational research reference and does not diagnose, treat, or prescribe. Consult a licensed clinician before considering any compound.

TB-500 Formats & Sourcing

The protocols above are written against the formats TB-500 is actually supplied in. Batch-specific Certificates of Analysis are issued per lot; always verify the strength on the label against the figures used here before calculating anything.

Format	Supplied as
Vial	10 mg lyophilized powder
Pen vial	Pre-reconstituted, 3 mL
Nasal spray	Pre-mixed, 0.2 mg per spray
Nasal spray — 5-pack	Bulk: five nasal spray units
Vial — 5-pack	Bulk: five vial units

5-packs are available for the nasal spray and vial formats. Strengths and formats are listed as sold; confirm against the product page and the batch COA.

Reference material for this protocol, with batch COA:

View TB-500 on Spyro Peptides →

Purity 99+% HPLC Batch COA available Research use only

References

Goldstein AL, et al. Thymosin β4: actin-sequestering protein and tissue repair. Ann N Y Acad Sci (2012).
Malinda KM, et al. Thymosin β4 accelerates wound healing. J Invest Dermatol (1999).
Bock-Marquette I, et al. Thymosin β4 and cardiac repair. Nature (2004).
World Anti-Doping Agency. Prohibited List 2025.